| Family Eye Care | |
|
200 Doctors Dr Ste K, Jacksonville, NC 28546-6308 | |
| (910) 353-0541 | |
| (910) 353-5353 |
| Full Name | Family Eye Care |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 200 Doctors Dr Ste K, Jacksonville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174030225 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Provider Name | George Conekin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1427016435 PECOS PAC ID: 7214142470 Enrollment ID: I20120330000434 |
News Archive
A new Joint Commission Sentinel Event Alert issued today urges health care leaders to step up efforts to prevent errors by taking the zero-defect approach used in other high-risk industries such as aviation and nuclear energy.
An intensive interdisciplinary outpatient program for managing chronic back pain has shown clinically significant results in a pilot study.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.
According to the Society of Actuaries, the leading cause of U.S. long-term care claims is Alzheimer's, the brain disease that renders over 5 million Americans unable to handle all the acts of daily living unaided. Who cares? Evidently President Obama does, having written a pro-active column in the Fall, 2010, issue of care ADvantage, published by the Alzheimer's Foundation of America.
› Verified 2 days ago
| Provider Name | Lloyd Allen Butler |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1396904132 PECOS PAC ID: 3476886821 Enrollment ID: I20190618000316 |
News Archive
A new Joint Commission Sentinel Event Alert issued today urges health care leaders to step up efforts to prevent errors by taking the zero-defect approach used in other high-risk industries such as aviation and nuclear energy.
An intensive interdisciplinary outpatient program for managing chronic back pain has shown clinically significant results in a pilot study.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.
According to the Society of Actuaries, the leading cause of U.S. long-term care claims is Alzheimer's, the brain disease that renders over 5 million Americans unable to handle all the acts of daily living unaided. Who cares? Evidently President Obama does, having written a pro-active column in the Fall, 2010, issue of care ADvantage, published by the Alzheimer's Foundation of America.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Family Eye Care 200 Doctors Dr Ste K, Jacksonville, NC 28546-6308 Ph: (910) 353-0541 | Family Eye Care 200 Doctors Dr Ste K, Jacksonville, NC 28546-6308 Ph: (910) 353-0541 |
News Archive
A new Joint Commission Sentinel Event Alert issued today urges health care leaders to step up efforts to prevent errors by taking the zero-defect approach used in other high-risk industries such as aviation and nuclear energy.
An intensive interdisciplinary outpatient program for managing chronic back pain has shown clinically significant results in a pilot study.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
Tethys Bioscience, a privately held company, announced today that it has closed a $25 million Series D round of financing led by aeris CAPITAL AG and including Wasatch Advisors as a new investor. All current investors, including MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield & Byers and Intel Capital participated in the round. Tethys also announced that it has appointed George Rehm, Managing Partner of aeris CAPITAL, to the Tethys Board of Directors.
According to the Society of Actuaries, the leading cause of U.S. long-term care claims is Alzheimer's, the brain disease that renders over 5 million Americans unable to handle all the acts of daily living unaided. Who cares? Evidently President Obama does, having written a pro-active column in the Fall, 2010, issue of care ADvantage, published by the Alzheimer's Foundation of America.
› Verified 2 days ago
Eyecarecenter Od Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 4130 Western Blvd, Jacksonville, NC 28546 Phone: 636-200-4393 Fax: 910-353-5459 | |
Sheri L Laughinghouse, OD Optometrist Medicare: Medicare Enrolled Practice Location: 561 Yopp Rd, Jacksonville, NC 28540 Phone: 910-353-2020 Fax: 910-355-2021 | |
Mission Vision Optometry, Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3301 Henderson Dr, Jacksonville, NC 28546 Phone: 910-939-2068 Fax: 910-939-2069 | |
Dr. Justin David Lane, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1345 Western Blvd Ste 120b, Jacksonville, NC 28546 Phone: 910-376-8229 | |
Dr. Jared A Taylor, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 409 Western Blvd, Suite 700, Jacksonville, NC 28546 Phone: 910-219-3937 | |
Dr. Patrick M Dooley, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 314 Jacksonville Mall, Jacksonville, NC 28546 Phone: 910-353-9200 Fax: 910-353-5459 |